Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Most gastrointestinal stromal tumors (GIST) are driven by activating mutations in Proto-oncogene c-KIT (KIT) or PDGFRA receptor tyrosine kinases (RTK).
• Imatinib, a tyrosine kinase inhibitor (TKI), revolutionized advanced GIST management but resistance emerges within 2 years via secondary mutations.
• De novo resistance occurs in some patients, including those with PDGFRA exon 18 mutations or lacking KIT/PDGFRA mutations.

Approach:

• Reviewing literature on medical management of high-risk localized and advanced GIST.
• Updating on clinical trial approaches for GIST treatment.
• Focusing on developing next-generation KIT/PDGFRA inhibitors and compounds targeting complementary pathogenic processes or epigenetic events.

Key Points:

• Resistance to imatinib in GIST is a significant clinical challenge, driven by secondary mutations in KIT or de novo alterations.
• Next-generation inhibitors are being developed to overcome resistance by targeting alternate receptor conformations and unique mutations.
• Research also explores compounds impacting complementary pathogenic processes and epigenetic events to combat GIST resistance.

Conclusions:

• Effective management of advanced GIST requires addressing both primary mutations and acquired resistance mechanisms.
• Ongoing clinical trials are crucial for evaluating novel therapeutic strategies against resistant GIST.
• Future directions involve combination therapies and targeting epigenetic modifications for improved GIST outcomes.